Violation Tracker Individual Record
Company:Boehringer Ingelheim Pharmaceuticals, Inc.
Date:December 20, 2017
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
Boehringer Ingelheim Pharmaceuticals, Inc. agreed to pay $13.5 million to settle multistate litigation alleging deceptive and misleading representation and off-label marketing of its prescription drugs.
Level of Government:state
Action Type:agency action
Agency:Multistate Attorneys General Case
Civil or Criminal Case:civil
HQ Country of Parent:Germany
Ownership Structure of Parent:privately held
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.